Loading stock data…
Repligen Corporation (RGEN)
$131.96-5.64 (-4.10%)
Market ClosedLast close Jul 24
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Repligen Corporation in the Healthcare sector is trading at $131.96 with a market capitalization of $6.9B. Wall Street consensus targets $178.05 (20 analysts), implying a +34.9% move over the next 12 months. The stock is currently 25% below its 52-week high of $175.77, remaining 5.7% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +34.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $194.25M↓ | $197.91M↑ | $188.81M↑ | $182.37M↑ | $169.17M |
| Gross Profit | $108.28M↑ | $103.83M↑ | $100.52M↑ | $91.14M↓ | $91.37M |
| Operating Income | $17.29M↑ | $16.35M↑ | $12.68M↑ | $5.96M↓ | $8.55M |
| Net Income | $8.33M↓ | $13.29M↓ | $14.91M↑ | $14.87M↑ | $5.83M |
Peer Comparison
JNJUNHPFE
Fundamentals
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatogr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
133.77
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.44%
Volume
Today's trading volume
1.34M
Recent News
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million
3 Cash-Producing Stocks That Concern Us
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and th
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen’s exposure to one of the faster-growing areas of bioprocessing. Presi